Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy express… Read more
Adicet Bio Inc (ACET) - Net Assets
Latest net assets as of December 2025: $159.21 Million USD
Based on the latest financial reports, Adicet Bio Inc (ACET) has net assets worth $159.21 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($192.35 Million) and total liabilities ($33.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $159.21 Million |
| % of Total Assets | 82.77% |
| Annual Growth Rate | 1.5% |
| 5-Year Change | -47.48% |
| 10-Year Change | -47.7% |
| Growth Volatility | 69.89 |
Adicet Bio Inc - Net Assets Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adicet Bio Inc (2008–2025)
The table below shows the annual net assets of Adicet Bio Inc from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $159.21 Million | -14.68% |
| 2024-12-31 | $186.61 Million | +9.66% |
| 2023-12-31 | $170.18 Million | -41.79% |
| 2022-12-31 | $292.34 Million | -3.56% |
| 2021-12-31 | $303.13 Million | +176.01% |
| 2020-12-31 | $109.83 Million | +281.94% |
| 2019-12-31 | $-60.37 Million | -157.93% |
| 2018-12-31 | $104.20 Million | +109.70% |
| 2017-12-31 | $49.69 Million | -83.68% |
| 2016-12-31 | $304.44 Million | +19.76% |
| 2015-12-31 | $254.21 Million | +8.83% |
| 2014-12-31 | $233.58 Million | +20.01% |
| 2013-12-31 | $194.64 Million | +15.86% |
| 2012-12-31 | $168.00 Million | +16.55% |
| 2011-12-31 | $144.15 Million | +15.92% |
| 2010-12-31 | $124.35 Million | -0.82% |
| 2009-12-31 | $125.38 Million | +1.39% |
| 2008-12-31 | $123.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adicet Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 851.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.01% |
| Other Comprehensive Income | $102.00K | 0.06% |
| Other Components | $773.79 Million | 486.02% |
| Total Equity | $159.21 Million | 100.00% |
Adicet Bio Inc Competitors by Market Cap
The table below lists competitors of Adicet Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VirTra Inc
NASDAQ:VTSI
|
$49.15 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
$49.18 Million |
|
Thai Coconut Public Company Limited
BK:COCOCO
|
$49.18 Million |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
$49.19 Million |
|
PEDEVCO Corp
NYSE MKT:PED
|
$49.12 Million |
|
Solytech Enterprise Corp
TW:1471
|
$49.10 Million |
|
BriQ Properties Real Estate Investment Company
AT:BRIQ
|
$49.10 Million |
|
LIG-ES SPAC
KQ:220260
|
$49.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adicet Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 186,609,000 to 159,210,000, a change of -27,399,000 (-14.7%).
- Net loss of 116,803,000 reduced equity.
- Other comprehensive income increased equity by 86,000.
- Other factors increased equity by 89,318,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-116.80 Million | -73.36% |
| Other Comprehensive Income | $86.00K | +0.05% |
| Other Changes | $89.32 Million | +56.1% |
| Total Change | $- | -14.68% |
Book Value vs Market Value Analysis
This analysis compares Adicet Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.31x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.07x to 0.31x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | $103.53 | $7.19 | x |
| 2009-12-31 | $103.64 | $7.19 | x |
| 2010-12-31 | $101.23 | $7.19 | x |
| 2011-12-31 | $112.68 | $7.19 | x |
| 2012-12-31 | $114.58 | $7.19 | x |
| 2013-12-31 | $129.66 | $7.19 | x |
| 2014-12-31 | $155.60 | $7.19 | x |
| 2015-12-31 | $162.74 | $7.19 | x |
| 2016-12-31 | $173.68 | $7.19 | x |
| 2017-12-31 | $29.47 | $7.19 | x |
| 2018-12-31 | $55.95 | $7.19 | x |
| 2019-12-31 | $-52.04 | $7.19 | x |
| 2020-12-31 | $240.06 | $7.19 | x |
| 2021-12-31 | $156.70 | $7.19 | x |
| 2022-12-31 | $113.86 | $7.19 | x |
| 2023-12-31 | $63.26 | $7.19 | x |
| 2024-12-31 | $33.98 | $7.19 | x |
| 2025-12-31 | $23.10 | $7.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adicet Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -73.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.21x
- Recent ROE (-73.36%) is below the historical average (-17.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 9.60% | 3.75% | 1.75x | 1.46x | $-567.90K |
| 2009 | 6.10% | 2.67% | 1.70x | 1.34x | $-5.53 Million |
| 2010 | 4.71% | 1.90% | 1.60x | 1.55x | $-7.38 Million |
| 2011 | 5.58% | 2.17% | 1.40x | 1.83x | $-7.11 Million |
| 2012 | 10.11% | 3.82% | 1.48x | 1.78x | $180.70K |
| 2013 | 11.47% | 4.47% | 1.54x | 1.66x | $2.86 Million |
| 2014 | 9.56% | 4.47% | 1.07x | 2.00x | $-1.03 Million |
| 2015 | 11.41% | 5.68% | 1.04x | 1.93x | $3.58 Million |
| 2016 | 0.00% | 0.00% | 1.01x | 1.78x | $-30.45 Million |
| 2017 | -67.98% | -6.05% | 10.12x | 1.11x | $-38.75 Million |
| 2018 | -8.92% | -113.67% | 0.07x | 1.06x | $-19.72 Million |
| 2019 | 0.00% | -2827.94% | 0.01x | 0.00x | $-22.10 Million |
| 2020 | -33.40% | -204.87% | 0.12x | 1.40x | $-47.66 Million |
| 2021 | -20.45% | -637.19% | 0.03x | 1.12x | $-92.31 Million |
| 2022 | -23.87% | -279.27% | 0.08x | 1.13x | $-99.02 Million |
| 2023 | -83.83% | 0.00% | 0.00x | 1.22x | $-159.68 Million |
| 2024 | -62.76% | 0.00% | 0.00x | 1.18x | $-135.78 Million |
| 2025 | -73.36% | 0.00% | 0.00x | 1.21x | $-132.72 Million |
Industry Comparison
This section compares Adicet Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adicet Bio Inc (ACET) | $159.21 Million | 9.60% | 0.21x | $49.12 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |